Regulatory Watch
A dated record of public regulatory developments around peptides, for context only.
This is a dated record of public regulatory developments for context. It is not legal or medical advice, and a recommendation is not an approval.
Topical peptide skincare is regulated as cosmetics in the US and UK and is unaffected by the compounding debate below.
The Ledger
- 2027-02-28Watchlist
Copper peptide GHK-Cu scheduled for FDA review
Copper peptide GHK-Cu is scheduled for FDA review by the end of February 2027. The review concerns specific uses and does not change the cosmetic status of topical copper peptide skincare in the US or UK.
Public regulatory calendar entry. Watchlist item, not yet reviewed.
- 2027-01-15Watchlist
Melanotan II review expected
A review of Melanotan II is expected in early 2027. Dermatologists have flagged published reports of changing moles associated with its use. Melanotan II is not a topical cosmetic peptide and is not sold through this platform.
Public dermatology literature and regulatory calendar, early 2027.
- 2026-07-01Regulation
FDA advisory committee recommended easing restrictions on 6 compounded injectable peptides
An FDA advisory committee recommended easing restrictions on 6 compounded injectable peptides. This is a recommendation, not an approval. No injectable peptide is approved on the strength of this recommendation, and it does not affect topical cosmetic skincare.
Public FDA advisory committee meeting, July 2026. A recommendation, not an approval.
- 2023-10-01Regulation
FDA restricted 19 peptides for compounding
The FDA added 19 peptides to its category 2 bulk drug substances list, restricting their use in compounding over safety concerns. The restrictions apply to compounded preparations and do not affect topical cosmetic skincare products.
Public FDA compounding policy update, 2023.